{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:47:40Z","timestamp":1759009660994},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"DOI":"10.1097\/qai.0b013e3181bd5ce1","type":"journal-article","created":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T08:32:45Z","timestamp":1267000365000},"page":"364-368","source":"Crossref","is-referenced-by-count":21,"title":["Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV\/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse"],"prefix":"10.1097","volume":"53","author":[{"given":"Pablo","family":"Labarga","sequence":"first","affiliation":[]},{"given":"Eugenia","family":"Vispo","sequence":"additional","affiliation":[]},{"given":"Pablo","family":"Barreiro","sequence":"additional","affiliation":[]},{"given":"Sonia","family":"Rodr\u00edguez-Novoa","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Pinilla","sequence":"additional","affiliation":[]},{"given":"Judit","family":"Morello","sequence":"additional","affiliation":[]},{"given":"Luz","family":"Mart\u00edn-Carbonero","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Tuma","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Medrano","sequence":"additional","affiliation":[]},{"given":"Vincent","family":"Soriano","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the HIV: the D:A:D study.","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"issue":"Suppl","key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection.","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group.","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury.","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients.","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1086\/595848","article-title":"New therapies for HCV infection.","volume":"48","author":"Soriano","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200401020-00009","article-title":"Pegylated interferon alpha 2b and ribavirin in HIV\/hepatitis C virus-coinfected non-responders and relapsers to IFN-based therapy.","volume":"18","author":"Myers","year":"2004","journal-title":"AIDS"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2006.09.009","article-title":"Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV\/HIV coinfected patients who failed previous IFN based therapy.","volume":"38","author":"Rodriguez-Torres","year":"2007","journal-title":"J Clin Virol"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/dkn262","article-title":"Efficacy of pegylated interferon and ribavirin for re-treatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.","volume":"62","author":"Crespo","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/01.qai.0000194238.15831.c7","article-title":"Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV\/hepatitis C virus-coinfected patients.","volume":"41","author":"de Ledinghen","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/FTD.0b013e31815bddf3","article-title":"Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.","volume":"29","author":"Morello","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl","key":"R22-11-20210131","first-page":"311A","article-title":"Response to high ribavirin dose in combination with peg-IFN alfa-2a for treatment of HCV genotype 1 previous non-responders.","volume":"46","author":"Hornfeldt","year":"2007","journal-title":"Hepatology"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modeling how ribavirin improves interferon response rates in hepatitis C virus infection.","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2893.2006.00806.x","article-title":"Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV\/HIV-coinfected patients.","volume":"14","author":"Ramos","year":"2007","journal-title":"J Viral Hepat"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.","volume":"13","author":"Maynard","year":"2008","journal-title":"Antivir Ther"},{"key":"R26-11-20210131","first-page":"2225","article-title":"Regression of liver fibrosis in hepatitis C virus\/HIV-coinfected patients after treatment with pegylated interferon plus ribavirin.","volume":"20","author":"Soriano","year":"2006","journal-title":"AIDS"},{"key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/135965350601100706","article-title":"Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV\/HIV-coinfected patients.","volume":"11","author":"Barreiro","year":"2006","journal-title":"Antivir Ther"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/135965350400900616","article-title":"Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.","volume":"9","author":"Soriano","year":"2004","journal-title":"Antivir Ther"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"The relationship of regression of cirrhosis to outcome in chronic hepatitis C.","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-201003010-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T16:10:16Z","timestamp":1685463016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201003010-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181bd5ce1","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}